The LEADER Trial (Once-Daily Liraglutide) The LEADER trial primarily assessed the cardiovascular safety of once-daily liraglutide compared to placebo [26]
Patients with diabetes experienced an average weight loss difference of 4-6.2%, while those without diabetes saw even more impressive results, ranging from 6.1% to 17.4% weight loss
Kim HJ, Koo KA, Park WS, Kang DM, Kim HS, Lee BY et al (2020) Anti-obesity activity of anthocyanin and carotenoid extracts from color-fleshed sweet potatoes
The most important substrates are pyruvate, lactate, glycerol and glucogenic amino acids (especially alanine)
Ahmad MF, Naseem N, Rahman I, Imam N, Younus H, Pandey SK, Siddiqui WA
One of the cited incidents involved a weight loss supplement that contained two undeclared active pharmaceutical ingredients